Lixumistat is under clinical development by Immunomet Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lixumistat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lixumistat overview
Lixumistat is under development for the treatment of gastrointestinal stromal tumor , castration-resistant prostate cancer (CRPC), recurrent glioblastoma, fibrosis and Idiopathic pulmonary fibrosis, pancreatic ductal adenocarcinoma, malignant glioma and BRAF-mutant malignant melanoma. The drug candidate is administered orally. It is a new molecular entity and acts by targeting epithelial-mesenchymal transition (EMT) process and oxidative phosphorylation (OXPHOS) in cancer cells. It was also under development for fibrotic diseases such as peritoneal fibrosis and hypertrophic scar. It was also under development for the treatment of pulmonary fibrosis, gastric cancer and diffuse large B-cell lymphoma.
Immunomet Therapeutics overview
Immunomet Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of novel products for cancer patients. The company’s pipeline product includes IM156 Lixumistat developed for the treatment of lung fibrosis, immuno-metabolism and cancer diseases like pancreatic cancer, glioblatoma multiforme, castrate resistant prostate cancer, and gastrointestinal stromal cancer. Immunomet Therapeutics’ product candidates are designed to combat cancers that target the resistant cancer subpopulation and immunosuppressive cells. The company’s novel technology is designed to disrupt cancer cell growth and improve anti-cancer immunity. It has operations across the US. Immunomet Therapeutics is headquartered in Houston, Texas, the US.
For a complete picture of Lixumistat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
